Evaluating antimicrobial duration for Gram-negative bacteremia in patients with neutropenia due to hematologic malignancy or hematopoietic stem cell transplantation
- PMID: 37279240
- DOI: 10.1111/tid.14085
Evaluating antimicrobial duration for Gram-negative bacteremia in patients with neutropenia due to hematologic malignancy or hematopoietic stem cell transplantation
Abstract
Background: In the management of Gram-negative bloodstream infection (GN-BSI), short antimicrobial courses have been increasingly demonstrated to be non-inferior to prolonged therapy, with lower risk of Clostridioides difficile infection (CDI) and emergence of multi-drug resistant (MDR) organisms. However, immunocompromised hosts were excluded from these studies. We investigated outcomes of short (≤10 days), intermediate (11-14 days), and prolonged (≥15 days) antimicrobial durations for GN-BSI in neutropenic patients.
Methods: A retrospective cohort study was conducted on neutropenic patients with monomicrobial GN-BSI between 2018 and 2022. The primary outcome was a composite of all-cause mortality and microbiologic relapse within 90 days after therapy completion. The secondary outcome was a composite of 90-day CDI and development of MDR-GN bacteria. Cox regression analysis with propensity score (PS) adjustment was used to compare outcomes between the three groups.
Results: A total of 206 patients were classified into short (n = 67), intermediate (n = 81), or prolonged (n = 58) duration. Neutropenia was predominantly secondary to hematopoietic stem cell transplantation (48%) or hematologic malignancy (35%). The primary sources of infection included intra-abdominal (51%), vascular catheter (27%), and urinary (8%). Most patients received definitive therapy with cefepime or carbapenem. No significant difference in the primary composite endpoint was observed for intermediate versus short (PS-adjusted hazard ratio [aHR] 0.89; 95% confidence interval [95% CI] 0.39-2.03) or prolonged versus short therapy (PS-aHR 1.20; 95% CI 0.52-2.74). There was no significant difference in the secondary composite endpoint of CDI or MDR-GN emergence.
Conclusion: Our data suggest that short antimicrobial courses had comparable 90-day outcomes as intermediate and prolonged regimens for GN-BSI among immunocompromised patients with neutropenia.
Keywords: Gram negative; antimicrobial stewardship; duration; immunocompromised; neutropenia; sepsis.
© 2023 Wiley Periodicals LLC.
Similar articles
-
Risk factors for positive follow-up blood cultures in Gram-negative bacteremia among immunocompromised patients with neutropenia.Transpl Infect Dis. 2024 Feb;26(1):e14203. doi: 10.1111/tid.14203. Epub 2023 Nov 27. Transpl Infect Dis. 2024. PMID: 38010744
-
Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population.Biol Blood Marrow Transplant. 2019 Oct;25(10):2091-2097. doi: 10.1016/j.bbmt.2019.06.021. Epub 2019 Jun 27. Biol Blood Marrow Transplant. 2019. PMID: 31255741
-
Prevalence of Resistant Gram-Negative Bacilli in Bloodstream Infection in Febrile Neutropenia Patients Undergoing Hematopoietic Stem Cell Transplantation: A Single Center Retrospective Cohort Study.Medicine (Baltimore). 2015 Nov;94(45):e1931. doi: 10.1097/MD.0000000000001931. Medicine (Baltimore). 2015. PMID: 26559260 Free PMC article.
-
Leptotrichia Bacteremia: 10-Year Retrospective Clinical Analysis and Antimicrobial Susceptibility Profiles.J Clin Microbiol. 2023 Feb 22;61(2):e0173322. doi: 10.1128/jcm.01733-22. Epub 2023 Jan 30. J Clin Microbiol. 2023. PMID: 36715514 Free PMC article. Review.
-
Bacterial Infections in the Stem Cell Transplant Recipient and Hematologic Malignancy Patient.Infect Dis Clin North Am. 2019 Jun;33(2):399-445. doi: 10.1016/j.idc.2019.02.011. Infect Dis Clin North Am. 2019. PMID: 31005135 Review.
Cited by
-
Bring it on again: antimicrobial stewardship in transplant infectious diseases: updates and new challenges.Antimicrob Steward Healthc Epidemiol. 2024 Jan 11;4(1):e3. doi: 10.1017/ash.2023.517. eCollection 2024. Antimicrob Steward Healthc Epidemiol. 2024. PMID: 38234416 Free PMC article. Review.
-
Risk factors for positive follow-up blood cultures in Gram-negative bacteremia among immunocompromised patients with neutropenia.Transpl Infect Dis. 2024 Feb;26(1):e14203. doi: 10.1111/tid.14203. Epub 2023 Nov 27. Transpl Infect Dis. 2024. PMID: 38010744
References
REFERENCES
-
- Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents. 2007;30(suppl 1):S51-S59.
-
- Trecarichi EM, Tumbarello M. Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact. Curr Opin Infect Dis. 2014;27(2):200-210.
-
- Perez F, Adachi J, Bonomo RA. Antibiotic-resistant gram-negative bacterial infections in patients with cancer. Clin Infect Dis. 2014;59(suppl 5):S335-S339.
-
- Gikas A, Samonis G, Christidou A, et al. Gram-negative bacteremia in non-neutropenic patients: a 3-year review. Infection. 1998;26(3):155-159.
-
- Kang CI, Kim SH, Park WB, et al. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microb Drug Resist. 2005;11(1):68-74.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
